ArticleJournal of gastrointestinal cancer2026
Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough bone metastases (BMs) are uncommon in colorectal cancer (CRC), they are a clinically significant problem. BMs are associated with a poor prognosis, and depending on the location, skeletal complications may occur. This study aims to evaluate the characteristics, treatment modalities, and prognostic factors affecting survival in patients with bone-metastatic CRC treated at a single institution. MATERIALS AND
methodsThis retrospective study included 59 patients diagnosed and followed up with bone-metastatic colorectal cancer at Marmara University Pendik Training and Research Hospital between January 2014 and December 2024. Demographic and clinical variables, including age, sex, tumor location, grade, mutation status, and metastatic spread, were examined. Bone Metastasis Progression-free survival (BM-PFS) and Bone Metastasis spesific overall survival (BM-OS) were assessed using the Kaplan-Meier method, and prognostic factors were assessed using Cox proportional hazard regression in univariate and multivariate models.
resultsMedian age of the patients was 59 years and 64.4% were male. The most common tumor involvements were sigmoid or descending colon (35.6%) and rectum (32.2%). BMs primarily involved the spinal vertebrae (49.1%) and pelvic bones (32.2%). Seventeen patients (28.8%) presented with de novo bone metastasis, and 44 patients (74.6%) had concurrent lymph node involvement. Antiresorptive therapy was administered to 15 patients (25.4%), and 49 (83.1%) received palliative radiotherapy. In survival analysis, age under 65 years was significantly associated with worse BM- PFS (HR = 2.44, 95% CI 1.30–4.57, p = 0.005) and BM-OS (HR = 1.85, 95% CI 1.01–3.40, p = 0.04). No significant correlation was observed with gender, tumor location, tumor grade or antiresorptive treatment use.
conclusionBMs in patients with colorectal cancer show a heterogeneous distribution. In this study, younger patients (< 65 years) had poorer BM-PFS and BM-OS, suggesting potential underlying mutations and biological aggressiveness. Larger, molecular-based prospective studies are needed to confirm these findings and guide optimal treatment strategies.
Indexed as
Identifiers
41944932What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.